Trial Profile
Single-center, Open and Single-dose Clinical Trial to Explore the Mass Balance of Oral Suspension of 300 mg /100 μCi [14C] Sulfatinib in Chinese Adult Male Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 25 Apr 2019
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary)
- Indications Biliary cancer; Neuroendocrine tumours; Solid tumours; Thyroid cancer
- Focus Pharmacokinetics
- Sponsors Hutchison MediPharma
- 21 Aug 2018 New trial record